SLC28A3 and exocrine pancreatic carcinoma: Variation rs7867504 in SLC28A3 was shown to be involved in gemcitabine pharmacobiology and toxicity in metastatic breast cancer patients receiving maintenance therapy [26] or in patients with pancreatic carcinoma [27].